ASH 2025 – Regeneron’s Lynozyfic shows front-line promise
Linker-MM4 data raise more questions about sequencing of therapies for multiple myeloma.
Epkinly gets a second-line follicular nod
And AbbVie and Genmab scoop their ASH presentation with new data.
More delays for Regeneron
The company gets another odronextamab knockback, while a key fianlimab readout is postponed.
FDA red and green lights: July 2025
Approvals come for Regeneron and Dizal, but Roche and Replimune see knockbacks.
The month ahead: August’s upcoming events
Jazz’s Chimerix buy faces its big test.
Columvi avoids its worst-case scenario
Roche’s drug is knocked back in second-line lymphoma, but keeps its third-line nod.
Pivotal T-cell engager readouts approach
Data on J&J’s Tecvayli and Pfizer’s Elrexfio in relapsed multiple myeloma are due soon.
Regeneron enters the T-cell engager arena
Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
